X4 PHARMACEUTICALS, INC Operating Cash Flow
X4 PHARMACEUTICALS, INC (XFOR) reported Operating Cash Flow of -$40.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$20.79M.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$19.60M.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$15.53M.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$27.82M.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) operating activities for fiscal 2025 was -$85.62M.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) operating activities for fiscal 2024 was -$130.90M.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) operating activities for fiscal 2023 was -$96.51M.
- X4 PHARMACEUTICALS, INC net cash provided by (used in) operating activities for fiscal 2022 was -$77.10M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$20.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$40.39M 10-Q · filed 2026-08-06 | -$55.91M derived: sum of 3 quarters · filed 2026-08-06 | -$83.74M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$19.60M 10-Q · filed 2026-05-06 | -$35.13M derived: sum of 2 quarters · filed 2026-05-06 | -$62.95M derived: sum of 3 quarters · filed 2026-05-06 | -$92.85M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$15.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$43.35M derived: sum of 2 quarters · filed 2026-03-17 | -$73.25M derived: sum of 3 quarters · filed 2026-08-06 | -$85.62M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | -$27.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$57.72M derived: sum of 2 quarters · filed 2026-08-06 | -$70.09M 10-Q · filed 2025-11-05 | -$103.09M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$29.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$42.27M 10-Q · filed 2026-08-06 | -$75.26M derived: sum of 3 quarters · filed 2026-08-06 | -$109.30M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | -$12.37M 10-Q · filed 2026-05-06 | -$45.36M derived: sum of 2 quarters · filed 2026-05-06 | -$79.39M derived: sum of 3 quarters · filed 2026-05-06 | -$143.29M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | -$32.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$67.03M derived: sum of 2 quarters · filed 2026-03-17 | -$130.93M derived: sum of 3 quarters · filed 2026-03-17 | -$130.90M 10-K · filed 2026-03-17 | |||
| 2024-09-30 | -$34.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$97.93M derived: sum of 2 quarters · filed 2025-11-05 | -$97.91M 10-Q · filed 2025-11-05 | -$159.28M derived: sum of 4 quarters · filed 2026-03-17 | |||
| 2024-06-30 | -$63.90M 10-Q · filed 2024-08-08 | -$63.87M 10-Q · filed 2025-08-08 | -$125.24M derived: sum of 3 quarters · filed 2026-03-17 | -$194.04M derived: sum of 4 quarters · filed 2026-03-17 | |||
| 2024-03-31 | -$33.60M 10-Q · filed 2025-05-01 | -$61.34M derived: sum of 2 quarters · filed 2026-03-17 | -$130.14M derived: sum of 3 quarters · filed 2026-03-17 | -$178.04M derived: sum of 4 quarters · filed 2026-03-17 | |||
| 2023-12-31 | -$27.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$96.55M derived: sum of 2 quarters · filed 2026-03-17 | -$144.45M derived: sum of 3 quarters · filed 2026-03-17 | -$96.51M 10-K · filed 2026-03-17 | |||
| 2023-09-30 | -$68.80M 10-Q · filed 2023-11-09 | -$116.70M derived: sum of 2 quarters · filed 2023-11-09 | -$68.77M 10-Q · filed 2024-11-13 | -$162.31M derived: sum of 4 quarters · filed 2025-03-26 | |||
| 2023-06-30 | -$47.90M 10-Q · filed 2023-08-10 | -$47.94M 10-Q · filed 2024-08-08 | -$93.50M derived: sum of 3 quarters · filed 2025-03-26 | -$112.81M derived: sum of 4 quarters · filed 2025-03-26 | |||
| 2023-03-31 | -$26.51M 10-Q · filed 2024-05-07 | -$45.60M derived: sum of 2 quarters · filed 2025-03-26 | -$64.91M derived: sum of 3 quarters · filed 2025-03-26 | -$83.39M derived: sum of 4 quarters · filed 2025-03-26 | |||
| 2022-12-31 | -$19.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$38.40M derived: sum of 2 quarters · filed 2025-03-26 | -$56.87M derived: sum of 3 quarters · filed 2025-03-26 | -$77.10M 10-K · filed 2025-03-26 | |||
| 2022-09-30 | -$19.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$37.78M derived: sum of 2 quarters · filed 2023-11-09 | -$58.01M 10-Q · filed 2023-11-09 | -$77.06M derived: sum of 4 quarters · filed 2024-03-21 | |||
| 2022-06-30 | -$18.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$38.70M 10-Q · filed 2023-08-10 | -$57.76M derived: sum of 3 quarters · filed 2024-03-21 | -$71.97M derived: sum of 4 quarters · filed 2024-03-21 | |||
| 2022-03-31 | -$20.23M 10-Q · filed 2023-05-04 | -$39.28M derived: sum of 2 quarters · filed 2024-03-21 | -$53.49M derived: sum of 3 quarters · filed 2024-03-21 | -$72.69M derived: sum of 4 quarters · filed 2024-03-21 | |||
| 2021-12-31 | -$19.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$33.26M derived: sum of 2 quarters · filed 2024-03-21 | -$52.46M derived: sum of 3 quarters · filed 2024-03-21 | -$70.91M 10-K · filed 2024-03-21 | |||
| 2021-09-30 | -$14.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$33.41M derived: sum of 2 quarters · filed 2022-11-03 | -$51.85M 10-Q · filed 2022-11-03 | -$69.36M derived: sum of 4 quarters · filed 2023-03-21 | |||
| 2021-06-30 | -$19.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$37.64M 10-Q · filed 2022-08-04 | -$55.15M derived: sum of 3 quarters · filed 2023-03-21 | -$69.47M derived: sum of 4 quarters · filed 2023-03-21 | |||
| 2021-03-31 | -$18.44M 10-Q · filed 2022-05-12 | -$35.95M derived: sum of 2 quarters · filed 2023-03-21 | -$50.28M derived: sum of 3 quarters · filed 2023-03-21 | -$61.73M derived: sum of 4 quarters · filed 2023-03-21 | |||
| 2020-12-31 | -$17.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | -$31.83M derived: sum of 2 quarters · filed 2023-03-21 | -$43.29M derived: sum of 3 quarters · filed 2023-03-21 | -$58.82M 10-K · filed 2023-03-21 | |||
| 2020-09-30 | -$14.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$25.79M derived: sum of 2 quarters · filed 2021-11-04 | -$41.31M 10-Q · filed 2021-11-04 | -$50.55M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2020-06-30 | -$11.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$26.99M 10-Q · filed 2021-08-03 | -$36.23M derived: sum of 3 quarters · filed 2022-03-17 | -$49.00M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2020-03-31 | -$15.53M 10-Q · filed 2021-05-06 | -$24.77M derived: sum of 2 quarters · filed 2022-03-17 | -$37.54M derived: sum of 3 quarters · filed 2022-03-17 | -$51.83M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2019-12-31 | -$9.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$22.01M derived: sum of 2 quarters · filed 2022-03-17 | -$36.30M derived: sum of 3 quarters · filed 2022-03-17 | -$48.05M 10-K · filed 2022-03-17 | |||
| 2019-09-30 | -$12.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$27.06M derived: sum of 2 quarters · filed 2020-11-05 | -$38.81M 10-Q · filed 2020-11-05 | -$45.55M derived: sum of 4 quarters · filed 2021-03-19 | |||
| 2019-06-30 | -$14.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$26.04M 10-Q · filed 2020-08-04 | -$32.78M derived: sum of 3 quarters · filed 2021-03-19 | -$39.50M derived: sum of 4 quarters · filed 2021-03-19 | |||
| 2019-03-31 | -$11.75M 10-Q · filed 2020-05-07 | -$18.48M derived: sum of 2 quarters · filed 2021-03-19 | -$25.20M derived: sum of 3 quarters · filed 2021-03-19 | -$30.99M derived: sum of 4 quarters · filed 2021-03-19 | |||
| 2018-12-31 | -$6.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | -$13.46M derived: sum of 2 quarters · filed 2021-03-19 | -$19.24M derived: sum of 3 quarters · filed 2021-03-19 | -$25.42M 10-K · filed 2021-03-19 | -$40.90M 10-K · filed 2019-03-11 | ||
| 2018-09-30 | -$6.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$12.50M derived: sum of 2 quarters · filed 2019-11-07 | -$18.69M 10-Q · filed 2019-11-07 | -$33.82M 10-Q · filed 2018-11-09 | -$25.03M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | -$5.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$11.96M 10-Q · filed 2019-08-07 | -$25.66M 10-Q · filed 2018-08-13 | -$18.31M derived: sum of 3 quarters · filed 2020-03-12 | -$23.40M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-03-31 | -$6.18M 10-Q · filed 2019-05-15 | -$12.53M derived: sum of 2 quarters · filed 2020-03-12 | -$17.62M derived: sum of 3 quarters · filed 2020-03-12 | ||||
| 2017-12-31 | -$6.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$11.44M derived: sum of 2 quarters · filed 2020-03-12 | -$21.31M 10-K · filed 2020-03-12 | -$27.87M 10-K · filed 2019-03-11 | |||
| 2017-09-30 | -$5.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$14.96M 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | -$9.87M 10-Q · filed 2018-08-13 | ||||||
| 2016-12-31 | -$21.64M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |